NEW YORK, NY / ACCESS Newswire / February 11, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, ...

By contrast, Novo Nordisk is both the developer and seller of Wegovy, while Viking Therapeutics's VK2735 has posted impressive results in testing and is now in the later stages of development. Wegovy ...

NEW YORK, NY / ACCESS Newswire / February 10, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors ...

There are no studies documenting the percentage of doctors taking the drugs. But physicians “are a good litmus test for drugs ...

Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has bee ...

CagriSema, considered a successor to Wegovy, is Novo Nordisk’s most likely route of gaining GLP-1RA market share back from ...

Novo Nordisk emissions grew 23% in 2024, the company said on Wednesday, and will keep rising through the end of the decade as ...

In commemoration of World Cancer Day 2025, a cancer organization, Project PINK BLUE - Health & Psychological Trust Centre, in collaboration with the Global Colorectal Cancer Association, premiered a ...

Novo Nordisk shares rose Wednesday after fourth-quarter earnings beat Wall Street's estimates, 2025 forecast came in line with expectations. Novo CEO Lars Fruergaard Jorgensen sees Wegovy supply ...

Robert F. Kennedy Jr., the nominee to lead the Department of Health and Human Services, made disputed claims before the ...

Even worse? It's outfitted with a laughably bad AI-concocted version of the pharmaceutical unicorn Novo Nordisk's logo, complete with incomprehensible gibberish. The company name is clearly ...

The Food and Drug Administration approved Novo Nordisk's Ozempic for patients with both chronic kidney disease and diabetes, expanding the use of the wildly popular injection in the U.S. The FDA ...